Ribavirin (R)

DRUG2 trials

Sponsors

Tibotec Pharmaceuticals, Ireland

Conditions

Hepatitis C

Phase 2

A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment

CompletedNCT00882908

Tibotec Pharmaceuticals, IrelandHepatitis C

Start: 2009-06-30End: 2011-04-30Updated: 2014-06-16

A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment

CompletedNCT00980330

Tibotec Pharmaceuticals, IrelandHepatitis C

Start: 2009-10-31End: 2011-08-31Updated: 2014-06-09

Related Papers

Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection

UNC Libraries2019-08-18

A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection.

2018-01-305 citations

Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study.

2017-06-021 citations

Pre-existence and Persistence of Resistant Minority Hepatitis C Virus Variants in Genotype 1-Infected Patients Treated With Simeprevir/Peginterferon/Ribavirin

Open Forum Infectious Diseases2016-01-015 citations

Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection.

2014-08-2614 citations

Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial.

2013-11-01167 citations

HCV RNA Quantification with Different Assays: Implications for Protease-Inhibitor-Based Response-Guided Therapy

Antiviral Therapy2013-08-0132 citations